HTFL heads into its May 13 earnings release with one storyline dominating everything else: a major insider is walking out the door.
Bain Capital Life Sciences liquidated roughly $58 million of its HeartFlow stake over three days at the end of April — selling nearly 2 million shares at prices between $29.18 and $30.51. The block sales slashed Bain's holding from 9.8% of shares to roughly 5.5%, one of the largest single-holder reductions seen in the stock since its listing. That kind of disposal, from a life-sciences-specialist fund that was a pre-IPO investor, draws attention regardless of the stated rationale.
The options market tells the opposite story, and the contrast is striking. Positioning has swung aggressively bullish into the print, with the put/call ratio at just 0.40 — well below its 20-day average of 1.01, and close to the bottom of the past year's range. Call volumes are running at roughly 2.5 times puts. That's a sharp reversal from early April, when the PCR topped 2.3 as uncertainty around tariffs and the broader macro backdrop pushed traders toward downside protection. The flip from defensive to offensive happened fast — in under three weeks.
Short interest adds a modestly cautious but hardly alarming backdrop. Bears hold about 6.5% of the free float, with days to cover near 4.6. The lending market remains relaxed: borrow costs are under 1% and availability is wide, meaning there is no meaningful squeeze pressure building. Short interest itself has drifted lower over the past month, down slightly from where it was in late March, though it ticked up 3% in the most recent session.
Analyst sentiment is uniformly positive — four buy ratings, no holds, no sells. William Blair initiated coverage at Outperform earlier this month. JP Morgan and Wells Fargo both trimmed targets to $35 following the March earnings release, while Canaccord raised its target to $43 and kept its Buy. The consensus return potential sits at roughly 28% from current levels, with the stock at $29.51. On the fundamental side, consensus estimates project revenue of around $220 million for the year — a growth story that trades at more than 13x EV/revenue with losses still running deep. A net loss of around $54 million is expected, and cash from operations remains negative.
The stock is up 10% over the past month and just over 1% year-to-date, having recovered sharply from its March post-earnings bounce of nearly 15%. The May 13 report is therefore a test of whether that AI-driven cardiac diagnostics growth narrative can continue to justify an enterprise value close to $2.5 billion — and whether the Street's bullish call options are better informed than Bain Capital's exit.
See the live data behind this article on ORTEX.
Open HTFL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
